Need Training?
Build a solid foundation in science, formulation and product development—find out more!
Most Popular in:
Animal Alternatives
Public Comments Requested for Development of NICEATM-ICCVAM 2013-2017 Five-Year Plan
Posted: December 7, 2011
The National Institute of Environmental Health Sciences (NIEHS) and the National Toxicology Program Interagency Center for the Evaluation of Alternative Toxicological Methods (NICEATM) invite public comments that can be considered by the Interagency Coordinating Committee on the Validation of Alternative Methods (ICCVAM) and the agencies' program offices in updating the NICEATM–ICCVAM 2008–2012 Five-Year Plan to develop the 2013–2017 Five-Year Plan.
A request for comments was published in the Federal Register on Nov. 21, 2011 (76 FR 71977). Comments are requested by Jan. 15, 2012, and can be submitted to NICEATM.
The plan addresses: identification of areas of high priority for new and revised non-animal and alternative assays to reduce, refine (enhance animal well-being and lessen or avoid pain and distress), and replace the use of animals in testing; and research, development, translation, and validation of new and revised non-animal and other alternative assays for integration into Federal agency testing programs.
Activities and achievements relevant to the goals and objectives identified in the current Five-Year Plan are noted in the 2008–2009 ICCVAM Biennial Report.
With regard to reducing, refining, and replacing animal use, ICCVAM identified and ranked the types of regulatory safety tests in the 2008–2012 plan that it considers to be the highest priority for the development and validation of alternative test methods. These priorities were based on the severity of unrelieved pain and distress and the number of animals involved in each type of testing. The highest priority testing areas include: acute eye irritation and corrosion; acute skin toxicity (including irritation/corrosion, sensitization, absorption); acute systemic toxicity (acute poisoning) by oral, dermal, and inhalation routes; and biologics and vaccines testing. Other priority testing areas include immunotoxicity, endocrine disruptors, pyrogenicity, reproductive/developmental toxicity, and chronic toxicity/carcinogenicity, and neurotoxicity as an area of interest.

